

DAFTAR PUSTAKA

1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. *Gastroenterology Rev.* 2019;14(2):89–103.
2. American Cancer Society. *Colorectal Cancer Facts & Figures 2020-2022.* 2020.
3. Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal Cancer Incidence Patterns in the United States, 1974-2013. *J Natl Cancer Inst.* 2017 Aug 1;109(8):1–6.
4. Gondhowiardjo S, Christina N, Ngakan ;, Ganapati PD, Hawariy S, Radityamurti F, et al. Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia. *JCO Global Oncol [Internet].* 2021;7:190–203. Available from: <https://ascopubs.org/go/authors/open-access>
5. Kojima M, Wakai K. Bowel Movement Frequency and risk of colorectal cancer in a large cohort study in Japanese Men and Woman. *Br J Cancer.* 2014;90:1397–401.
6. Artemev A, Naik S, Pougno A, Honnavar P, Shanbhag NM. The Association of Microbiome Dysbiosis With Colorectal Cancer. *Cureus.* 2022 Feb 12;14(2):1–10.
7. Barbara K, Stefan W. Colon Cancer Microbiome Landscaping: Differences in Right- and Left-Sided Colon Cancer and a Tumor Microbiome-Ileal Microbiome Association. *Int J Mol Sci.* 2023;24(3265).
8. Zenger S, Balik E, Bugra D. Complete mesocolic excision. *Ann Laparosc Endosc Surg.* 2019;4:70.
9. Terry P. Total mesorectal excision: technical aspects. *Canadian Medical Association.* 2013;130–7.
10. Robert B, Frank H. *Netter's Surgical Anatomy Review PRN.* 2nd ed. New York: Elsevier; 2017.
11. Fleming M, Ravula S. *Colorectal Carcinoma : Pathologic Aspects.* Pioneer Bioscience Publishing Company. 2018;3(3):153–73.
12. Suwaanabol P, Regenbogen S. Anorectal Physiology. In: Steele S, Hull H, Hyman N, Maykel J, Read T, Whitlow C, editors. *The ASCRS Textbook of Colon and Rectal Surgery.* Cham: Springer; 2022. p. 43.
13. Global Cancer Observatory. *GLOBOCAN 2022: Rectum Cancer.* 2022.
14. Lotfollahzadeh S, Kashyap S, Tsois A, Recio-Boiles A, Babiker H. Rectal cancer [Internet]. *StatPearls [Internet].* 2023 [cited 2024 Mar 30]. p. 1–18. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK493202/>

15. Rahadiani N, Habiburrahman M, Abdullah M, Jeo WS, Stephanie M, Handjari DR, et al. Analysing 11 years of incidence trends, clinicopathological characteristics, and forecasts of colorectal cancer in young and old patients: a retrospective cross-sectional study in an Indonesian national referral hospital. *BMJ Open*. 2022 Sep 7;12(9):1–22.
16. Anthonysamy M, Maker L, Gotra I, Saputra H. Prevalence of colorectal carcinoma based on microscopic type, sex, age and anatomical location in Sanglah General Hospital. *Intisari Sains Medis* [Internet]. 2020;11(1):272–6. Available from: <http://isainsmedis.id/>
17. Sawicki T, Ruskowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. *Cancers (Basel)*. 2021 May 1;13:1–23.
18. American Cancer Society. *Cancer Facts & Figures 2024*. 2024.
19. Zaborowski AM, Murphy B, Creavin B, Rogers AC, Kennelly R, Hanly A, et al. Clinicopathological features and oncological outcomes of patients with young-onset rectal cancer. *British Journal of Surgery*. 2020 Apr 1;107:606–12.
20. Feeney G, Sehgal R, Sheehan M, Hogan A, Regan M, Joyce M, et al. Neoadjuvant radiotherapy for rectal cancer management. *World J Gastroenterol*. 2019 Sep 7;25(33):4850–69.
21. Kementerian Kesehatan Republik Indonesia. *Panduan Pelayanan Klinis Kanker Rektum*. 2018.
22. Shin JK, Huh JW, Lee WY, Yun SH, Kim HC, Cho YB, et al. Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer. *Sci Rep*. 2022 Dec 1;12(7145):1–10.
23. Kementerian Kesehatan Republik Indonesia. *Pedoman nasional pelayanan kedokteran tata laksana kanker kolorektal*. Jakarta; 2019.
24. Osman MA, Neoh HM, Mutalib NSA, Chin SF, Jamal R. 16S rRNA gene sequencing for deciphering the colorectal cancer gut microbiome: Current protocols and workflows. *Front Microbiol*. 2018 Apr 27;9(767):1–10.
25. Siddiqui R, Boghossian A, Alharbi AM, Alfahemi H, Khan NA. The Pivotal Role of the Gut Microbiome in Colorectal Cancer. *Biology (Basel)*. 2022 Nov 1;11(1642):1–16.

26. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. *Nat Rev Gastroenterol Hepatol*. 2019 Nov 1;16(11):690–704.
27. Cheng Y, Ling Z, Li L. The Intestinal Microbiota and Colorectal Cancer. *Front Immunol*. 2020 Nov 30;11:1–13.
28. Liu Y, Li X, Yang Y, Liu Y, Wang S, Ji B, et al. Exploring Gut Microbiota in Patients with Colorectal Disease Based on 16S rRNA Gene Amplicon and Shallow Metagenomic Sequencing. *Front Mol Biosci*. 2021 Jul 9;8:1–12.
29. Rebersek M. Gut microbiome and its role in colorectal cancer. *BMC Cancer*. 2021 Dec 1;21(1325):1–13.
30. Zou S, Fang L, Lee MH. Dysbiosis of gut microbiota in promoting the development of colorectal cancer. *Gastroenterol Rep (Oxf)*. 2018 Feb 1;6(1):1–12.
31. Pandey H, Tang DWT, Wong SH, Lal D. Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities. *Cancers (Basel)*. 2023 Feb 1;15(866):1–44.
32. Clay SL, Fonseca-Pereira D, Garrett WS. Colorectal cancer: The facts in the case of the microbiota. *Journal of Clinical Investigation*. 2022 Feb 15;132(4):1–10.
33. Drewes JL, White JR, Dejea CM, Fathi P, Iyadorai T, Vadivelu J, et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. *NPJ Biofilms Microbiomes*. 2017 Dec 1;3(34):1–13.
34. Fan X, Jin Y, Chen G, Ma X, Zhang L. Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer. *Digestion*. 2021 Jun 1;102(4):508–15.
35. Kosumi K, Mima K, Baba H, Ogino S. Dysbiosis of the gut microbiota and colorectal cancer: the key target of molecular pathological epidemiology. *J Lab Precis Med*. 2018 Sep;3(76):1–5.
36. Cong J, Zhu H, Liu D, Li T, Zhang C, Zhu J, et al. A pilot study: Changes of gut microbiota in post-surgery colorectal cancer patients. *Front Microbiol*. 2018 Nov 20;9(2777):1–11.
37. Romo JA, Figueroa Avendaño CE, López LA, Mesa N, González-Muñoz A, Baquero D, et al. Features and outcomes of rectal cancer patients treated in a hospital in Bogotá, Colombia: a retrospective cohort study. *Sci Rep*. 2023 Dec 1;13(14828):1–6.
38. Wijeratne DT, Gunasekara S, Booth CM, Berry S, Jalink M, Carson LM, et al. Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri

Lanka: Results From a Hospital-Based Cancer Registry. *JCO Glob Oncol*. 2022 May;8:1–7.

39. Bong JW, Ju Y, Seo J, Lee JA, Kang SH, Lee S Il, et al. Clinical characteristics of rectal cancer patients with neoadjuvant chemoradiotherapy: A nationwide population-based cohort study in South Korea. *Ann Surg Treat Res*. 2021 May 1;100(5):282–90.
40. Patel M, McSorley ST, Park JH, Roxburgh CSD, Edwards J, Horgan PG, et al. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. *Br J Cancer*. 2018 Mar 6;118(5):705–12.
41. Wang Z, Dan W, Zhang N, Fang J, Yang Y. Colorectal cancer and gut microbiota studies in China. *Gut Microbes*. 2023;15(1):1–24.
42. Qu R, Zhang Y, Ma Y, Zhou X, Sun L, Jiang C, et al. Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer. *Advanced Science*. 2023 Aug 15;10:1–21.
43. Jahani-Sherafat S, Alebouyeh M, Moghim S, Amoli HA, Ghasemian-Safaei H. Role of gut microbiota in the pathogenesis of colorectal cancer; a review article. *Gastroenterol Hepatol Bed Bench*. 2018;11(2):101–9.
44. Png CW, Chua YK, Law JH, Zhang Y, Tan KK. Alterations in co-abundant bacteriome in colorectal cancer and its persistence after surgery: a pilot study. *Sci Rep*. 2022 Dec 1;12(1):1–13.
45. Tesolato S, Ortega-Hernández A, Gómez-Garre D, Claver P, De Juan C, la Serna S De, et al. Gut microbiota profiles in feces and paired tumor and non-tumor tissues from Colorectal Cancer patients. Relationship to the Body Mass Index. *PLoS One*. 2023 Oct 1;18(10):1–15.
46. Koliarakis I, Athanasakis E, Sgantzios M, Mariolis-Sapsakos T, Xynos E, Chrysos E, et al. Intestinal microbiota in colorectal cancer surgery. *Cancers (Basel)*. 2020 Oct 1;12(10):1–23.
47. Gupta VK, Kim M, Bakshi U, Cunningham KY, Davis JM, Lazaridis KN, et al. A predictive index for health status using species-level gut microbiome profiling. *Nat Commun*. 2020 Dec 1;11(1).
48. Bidell MR, Hobbs ALV, Lodise TP. Gut microbiome health and dysbiosis: A clinical primer. Vol. 42, *Pharmacotherapy*. American College of Clinical Pharmacy; 2022. p. 849–57.

49. Balmant BD, Fonseca DC, Rocha IM, Callado L, Torrinhas RSM de M, Waitzberg DL. Dys-R Questionnaire: A Novel Screening Tool for Dysbiosis Linked to Impaired Gut Microbiota Richness. *Nutrients*. 2023 Oct 1;15(19).
50. Zheng Z, Hu Y, Tang J, Xu W, Zhu W, Zhang W. The implication of gut microbiota in recovery from gastrointestinal surgery. Vol. 13, *Frontiers in Cellular and Infection Microbiology*. Frontiers Media S.A.; 2023.
51. Suparan K, Sriwichain S, Chattipakorn N, Chattipakorn SC. Human Blood Bacteriome: Eubiotic and Dysbiotic States in Health and Diseases. Vol. 11, *Cells*. MDPI; 2022.

